7th November 2019

Mirada Medical Announces Appointment of Dr Amato Giaccia as Chair of Medical Advisory Board

Oxford, United Kingdom, November 7, 2019 – Mirada Medical, a global leader in Artificial Intelligence (AI) software for the treatment of cancer, has announced today that the company has appointed Dr Amato J. Giaccia to the position of Chair of the company’s Strategic Medical Advisory Board.

Dr Giaccia is currently Director of the Institute of Radiation Oncology at Oxford University, having previously held the position of Director of the Division of Radiation & Cancer Biology at the University of Stanford, California.

Mirada Medical CEO, Hugh Bettesworth said, “We are honored to welcome Amato to the team. His input and insight will be invaluable to us as we continue to develop our AI-software products to deliver ever improving cancer care support for oncologists and their patients”.


Dr. Amato J. Giaccia said, “Mirada Medical are world leaders in using artificial intelligence to make cancer treatment planning more consistent and more accurate. I am delighted to join the team that has pioneered the use of AI for oncology treatment planning, and which has proved so many times over its ability to deliver real clinical benefit in everyday practice”.

- ENDS -

Mirada Medical, DLCExpert, RTx and Workflow Box are trademarks of Mirada Medical Ltd.


 About Mirada Medical

Mirada Medical is a leading international brand in medical imaging. The company develops advanced technology applications that help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.

The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment, and plan radiation therapy or surgical intervention. Mirada’s advanced technology products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.

Mirada’s advanced software products that target cancer care are in daily clinical use at over 1400 hospitals worldwide.

About Mirada Medical’s Strategic Advisory Board

Mirada Medical’s Strategic Advisory Board has been assembled to drive forward its clinical strategy for the deployment of AI in the treatment of cancer. The Board, chaired by Dr. Amato J. Giaccia, Director of the Institute of Radiation Oncology at Oxford University - is composed of accomplished leaders in the field of radiation oncology and medical imaging with appointments including:

  • Thomas Buchholz, M.D., Medical Director of the Scripps MD Anderson Cancer Center
  • Dan Fass, CEO of Princeton Healthcare Alliance (PHA)
  • Carlo Greco, Director of Clinical Research at the Champalimaud Centre for the Unknown (CCU)
  • Penny Kechagioglou, Chief Medical Officer at Genesis Care UK
  • Philip Poortsmans, M.D., PhD, Head of the Department of Radiation Oncology at the Institut Curie
  • Marc Posner, Medical Director of the Department of Radiation Oncology at Nortwestern Lake Forest Hospital


For more information, please contact:

Annamaria Albano

Mirada Medical Ltd